Bild 3

anfass Life Technologies biotech portfolio takes off 2021

01.03.2022 Solothurn     Swiss Biotech Company abc biopply reports revenues in 2021 more than doubled in its core business with its preclinical 3D tumor models. The company has started offering these specialized CRO services to its biotech and pharma clients since 2019. (read article in startupticker here).

The extraordinary market success of the 3D CoSeedis™ technology confirms a trend in the field of drug discovery that calls for new and more native 3D models, to better predict later clinical success of preclinically active compounds. The 3D CoSeedis™ Preclinical Models fulfill these requirements in an exemplary way and at the same time help the customers to reduce time and financial expenses at the earliest stage possible. The company attributes its extraordinary success in part to the increased need for outsourcing last year due to the ongoing pandemic and the associated work restrictions, including at major international customers. abc biopply offers its 3D CoSeedis™ assay portfolio as a CRO service or licenses the 3D models to its customers for in-house use. (see press release here).